LIXTE Biotechnology Holdings has leveraged its sponsorship of the inaugural Good Health: Mind, Body & Soul Summit on February 19 at Morehouse College to reinforce its commitment to health equity and community engagement. The invitation-only event, inspired by De La Soul’s legacy and attended by leading clinicians, researchers, and advocates, underscores LIXTE’s positioning beyond the laboratory. Geordan Pursglove, LIXTE’s CEO, highlighted the convergence of culture and oncology innovation, noting that the company’s first-in-class PP2A inhibitor, LB-100, and its European R&D arm LIORA will benefit from deeper connections with communities that experience disproportionate cancer burdens.

LIXTE’s core asset, LB-100, is progressing through proof-of-concept trials in ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma, with multiple cohorts already reporting tolerability at anti-cancer doses. Earlier preclinical data demonstrated enhanced chemosensitivity in xenograft models, results that have attracted interest from leading academic centers. Meanwhile, LIXTE’s wholly owned subsidiary Liora Technologies Europe is developing the LiGHT System, an electronically controlled proton therapy platform believed to improve tumor targeting precision. Together, these programs underpin a comprehensive patent portfolio in activation lethality and proton therapy innovation.

At the DealFlow Discovery Conference on January 28–29 in Atlantic City, CEO Geordan Pursglove will conduct one-on-one meetings with institutional and family-office investors to discuss LIXTE’s late-stage pipeline and upcoming milestones. The conference appearance follows a 35% increase in investor inquiries since the company reported its Q4 oncology update in December. LIXTE’s investor relations team has scheduled more than 20 meetings over the two days, reflecting strong demand for deeper diligence into LB-100’s mechanistic differentiation and Liora’s LiGHT System.

Investors should watch for interim safety and efficacy readouts from LB-100’s ongoing cohorts, expected in Q2 2026, and initial technical validation of the LiGHT System in a first-in-human feasibility study slated for mid-year. With approximately $28 million in cash and equivalents as of December 31, 2025, LIXTE projects runway into late 2027, assuming no additional fundraising. Management has signaled its openness to strategic partnerships to accelerate global development and commercialization of both LB-100 and Liora’s proton therapy technology.